Cargando…

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?

BACKGROUND: To account for interindividual variability in the pharmacokinetics (PK) of factor concentrates, PK‐guided dosing is increasingly implemented in haemophilia patients. Calculations are based on provided label potency, but legislation allows a potency difference of ±20% between label and ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goedhart, Tine M.H.J., Bukkems, Laura H., van Moort, Iris, Spence, Colin C., Zwaan, Michel C., de Maat, Moniek P.M., Mathôt, Ron A.A., Cnossen, Marjon H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546314/ https://www.ncbi.nlm.nih.gov/pubmed/35526235 http://dx.doi.org/10.1111/hae.14575

Ejemplares similares

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020)

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice
por: Goedhart, Tine M. H. J., et al.
Publicado: (2021)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Analytical variation in factor VIII one‐stage and chromogenic assays: Experiences from the ECAT external quality assessment programme
por: van Moort, Iris, et al.
Publicado: (2018)

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation
por: de Laat-Kremers, Romy M. W., et al.
Publicado: (2021)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study
por: Heijdra, Jessica M, et al.
Publicado: (2022)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
por: Donners, Anouk, et al.
Publicado: (2023)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients
por: Preijers, Tim, et al.
Publicado: (2021)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia
por: Zaher, Galila, et al.
Publicado: (2012)

Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
por: Chao, Ta-Chung, et al.
Publicado: (2023)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study
por: van Velzen, Alice S., et al.
Publicado: (2020)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
por: Iioka, F, et al.
Publicado: (2014)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
por: Romanová, Gabriela, et al.
Publicado: (2023)

A Novel Missense Mutation, E1623G, in the Human Factor VIII Gene Associated With Moderate Haemophilia A
por: Onsori, Habib, et al.
Publicado: (2014)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7pe1kmlvt8fmsro1copu0e9d4o